timm17a
Introduction
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">timm17a</th>
</tr>
<tr>
<td class="label">Gene Symbol</td>
<td>TIMM17A</td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Translocase of Inner Mitochondrial Membrane 17A</td>
</tr>
<tr>
<td class="label">Aliases</td>
<td>TIM17A, TIM17, Pdr3p</td>
</tr>
<tr>
<td class="label">Chromosomal Location</td>
<td>1q32.1</td>
</tr>
<tr>
<td class="label">NCBI Gene ID</td>
<td>10628</td>
</tr>
<tr>
<td class="label">Ensembl ID</td>
<td>ENSG00000139360</td>
</tr>
<tr>
<td class="label">UniProt ID</td>
<td>O60830 (TIM17_HUMAN)</td>
</tr>
<tr>
<td class="label">Gene Type</td>
<td>Protein coding</td>
</tr>
<tr>
<td class="label">Transcript Length</td>
<td>1,047 bp (mRNA)</td>
</tr>
<tr>
<td class="label">Protein Length</td>
<td>171 amino acids</td>
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>~17 kDa</td>
</tr>
<tr>
<td class="label">Component</td>
<td>Function</td>
</tr>
<tr>
<td class="label">TIMM22</td>
<td>Central channel protein (307 aa)</td>
</tr>
<tr>
<td class="label">TIMM17A</td>
<td>Core channel component, import of polytopic proteins</td>
</tr>
<tr>
<td class="label">TIMM17B</td>
<td>Paralog of TIMM17A, redundant function</td>
</tr>
<tr>
<td class="label">TIMM50</td>
<td>IMS receptor, connects to TIM23 complex</td>
</tr>
<tr>
<td class="label">TIMM8A/DJD1</td>
<td>IMS chaperone, interacts with TIM22</td>
</tr>
<tr>
<td class="label">TIMM8B</td>
<td>Second mitochondrial import protein</td>
</tr>
<tr>
<td class="label">TIMM9</td>
<td>Chaperone in IMS</td>
</tr>
<tr>
<td class="label">TIMM10</td>
<td>Chaperone in IMS</td>
</tr>
<tr>
<td class="label">Partner</td>
<td>Interaction Type</td>
</tr>
<tr>
<td class="label">TIMM22</td>
<td>Stable complex</td>
</tr>
<tr>
<td class="label">TIMM17B</td>
<td>Paralog interaction</td>
</tr>
<tr>
<td class="label">TIMM50</td>
<td>Regulatory</td>
</tr>
<tr>
<td class="label">TIMM9</td>
<td>Chaperone binding</td>
</tr>
<tr>
<td class="label">TIMM10</td>
<td>Chaperone binding</td>
</tr>
<tr>
<td class="label">TIMM8A</td>
<td>IMS complex</td>
</tr>
<tr>
<td class="label">TIMM8B</td>
<td>IMS complex</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/heart-failure" style="color:#ef9a9a">Heart Failure</a>, <a href="/wiki/ms" style="color:#ef9a9a">Ms</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">44 edges</a></td>
</tr>
</table>
TIMM17A (Translocase of Inner Mitochondrial Membrane 17A) is an essential component of the TIM22 translocase complex located in the mitochondrial inner membrane. This complex is responsible for the import and insertion of a specific class of inner membrane proteins—primarily mitochondrial carrier proteins and other polytopic membrane proteins essential for mitochondrial metabolism. The TIM22 complex represents one of several mitochondrial protein import pathways, each specializing in different substrate classes and mechanisms.
The discovery of TIMM17A and its paralog TIMM17B established the foundation for understanding how mitochondria import the hundreds of proteins required for their function. Given that mitochondria are essential for cellular energy production, metabolic regulation, and apoptosis, defects in mitochondrial protein import have profound consequences for cellular health.[@l2024] This has made TIMM17A and the TIM22 complex a focus of research in neurodegenerative diseases, where mitochondrial dysfunction is a central pathological feature.
This comprehensive review covers TIMM17A structure and function, its role in the TIM22 complex, disease associations, therapeutic implications, and research directions.
Pathway / Interaction Diagram
Mermaid diagram (expand to render)
Gene and Protein Overview
Gene Structure
The TIMM17A gene consists of 6 exons spanning approximately 10 kb on chromosome 1. The encoded protein is a small inner membrane protein with two predicted transmembrane domains, characteristic of the Tim17/Tim22/Tim23 family.
Protein Structure
TIMM17A belongs to the small Tim protein family (Tim17, Tim22, Tim23, Tim50) characterized by:
Structural features:
- Two trans membrane α-helices spanning residues 40-62 and 80-102
- Short intermembrane space loops
- Conserved DExD/H motif in the N-terminal region
- C-terminal domain facing the matrix
Topology:
- N-terminus: faces the intermembrane space (IMS)
- Two transmembrane helices: embedded in the inner membrane
- C-terminus: extends into the matrix
This topology allows TIMM17A to function as part of a dynamic channel that undergoes conformational changes during the protein import cycle.
Evolutionary Conservation
TIMM17A is highly conserved across eukaryotes:
- Humans: TIMM17A (171 aa) and TIMM17B (171 aa) paralogs
- Mice: Tim17a and Tim17b
- Drosophila: Tim17
- Saccharomyces cerevisiae: Tim17 (145 aa)
- Plants: TIM17 homologs
The presence of two paralogs in mammals (TIMM17A and TIMM17B) suggests functional specialization, with TIMM17A being more highly expressed in neuronal tissues.
The TIM22 Translocase Complex
Complex Composition
The TIM22 complex (also called the carrier translocase or inner membrane translocase) consists of:
The complex has an estimated molecular weight of ~500 kDa and exists as a stable oligomeric structure in the inner membrane.
Import Mechanism
The TIM22 complex mediates the import of mitochondrial carrier proteins, including:
Substrates:
- ADP/ATP translocase (ANT1-4)
- Phosphate carrier (PiC)
- Mitochondrial dicarboxylate carrier (DIC)
- Tricarboxylate carrier (CTC)
- Other metabolite carriers
Import pathway:
Recognition: Precursor proteins are recognized in the cytosol by mitochondrial carrier proteins (MCPs)
Translocation: Precursors traverse the TOM complex in the outer membrane
Chaperone capture: TIM9/TIM10 chaperone complex in IMS shields hydrophobic transmembrane segments
Docking: The precursor-TIM9/TIM10 complex docks onto TIM22 complex
Insertion: Sequential transmembrane segments are inserted into the inner membrane
Release: Completed carrier protein is released into the lipid bilayerThis pathway is distinct from the TIM23 complex, which imports proteins with N-terminal targeting signals.
Energy Requirements
The TIM22 import requires multiple energy sources:
- ATP: Required in the cytosol for chaperone function (Hsp70)
- Membrane potential (Δψ): Essential for insertion of positively charged transmembrane segments
- Proton gradient: Indirect role through ATP synthesis
The dependence on membrane potential makes the TIM22 complex particularly sensitive to mitochondrial dysfunction.
Cellular Functions
TIMM17A and the TIM22 complex are essential for mitochondrial metabolic function:
Carrier protein import:
- ADP/ATP translocase (ANT): Exports ATP, imports ADP
- Phosphate carrier: Imports inorganic phosphate for ATP synthesis
- Dicarboxylate carrier: Malate, succinate transport
- Tricarboxylate carrier: Citrate, isocitrate transport
- Pyruvate carrier: Links glycolysis to mitochondrial metabolism
- Many others (total ~50 carriers)
Metabolic consequences of import defects:
- Impaired oxidative phosphorylation
- Disrupted metabolite exchange
- Reduced ATP production
- Metabolic inflexibility
Energy Production
By enabling carrier protein import, TIMM17A directly supports:
- Oxidative phosphorylation: Essential for ATP production
- Krebs cycle function: Metabolite transport
- Fatty acid oxidation: Mitochondrial lipid metabolism
- Gluconeogenesis: Mitochondrial metabolic pathways
Neurons are particularly dependent on oxidative phosphorylation, making TIMM17A function critical for neuronal survival.[@mc2025]
Apoptosis Regulation
The TIM22 complex imports several proteins involved in apoptosis:
- VDAC: Voltage-dependent anion channel in outer membrane
- Certain Bcl-2 family proteins: Regulated by mitochondrial localization
- AIF: Apoptosis-inducing factor imported via TIM22
Dysregulation of TIMM17A can therefore affect the balance between cell survival and death.
Expression Patterns
Tissue Distribution
TIMM17A is expressed ubiquitously with highest levels in:
High expression:
- Brain (cerebral cortex, hippocampus, cerebellum)
- Heart (cardiac muscle)
- Skeletal muscle
- Liver
- Kidney
- Testis
Moderate expression:
- Lung
- Pancreas
- Adrenal gland
- Thyroid
This broad expression reflects the universal requirement for mitochondrial function.
Cellular Localization
Within cells, TIMM17A is localized to:
- Mitochondrial inner membrane
- Mitochondrial cristae membranes
- Contact sites between inner and outer membranes
Subcellular fractionation studies confirm >95% mitochondrial localization.
Developmental Regulation
TIMM17A expression is dynamically regulated:
- Embryonic development: Essential for viability
- Postnatal brain: High expression in developing neurons
- Aging: Variable changes reported
- Cellular stress: Often upregulated as compensatory response
Conditional knockout studies show that TIMM17A is essential for embryonic development.
Disease Associations
Alzheimer's Disease
Multiple mechanisms link TIMM17A to AD pathogenesis:
Mitochondrial dysfunction in AD:
- Early and prominent feature of AD neuropathology
- Impaired glucose metabolism in AD brains
- Reduced oxidative phosphorylation in neurons
-mtDNA mutations accumulate in AD
Import deficits in AD:
- TIMM17A expression altered in AD brain
- Impaired carrier protein import affects metabolic function
- Amyloid-beta directly affects mitochondrial import machinery
- Tau pathology disrupts mitochondrial dynamics
Therapeutic implications:
- Enhancing mitochondrial protein import may improve neuronal function
- Small molecules to enhance TIM22 complex activity under investigation
- Gene therapy approaches for TIMM17A upregulation
Parkinson's Disease
The relationship between TIMM17A and PD is particularly relevant:
Mitochondrial dysfunction in PD:
- Complex I deficiency in substantia nigra
- PINK1/Parkin pathway monitors mitochondrial quality
- PD-causing mutations affect mitochondrial function
- Environmental toxins (MPTP, rotenone) target mitochondria
TIMM17A in PD models:
- Altered expression in PD models
- Genetic variants associated with PD risk
- Impaired carrier protein import in dopaminergic neurons
Therapeutic approaches:
- Mitochondrial enhancement strategies
- CoQ10 and other mitochondrial supplements
- Exercise enhances mitochondrial function
Amyotrophic Lateral Sclerosis
TIMM17A and mitochondrial import in ALS:
- Mitochondrial dysfunction in motor neurons
- Impaired protein import in ALS models
- Energy deficits contribute to motor neuron vulnerability
- TIMM17A as potential therapeutic target
Other Neurodegenerative Conditions
Huntington's disease:
- Mitochondrial dysfunction in striatal neurons
- Altered TIMM17A expression in HD models
- Metabolic deficits contribute to pathogenesis
Frontotemporal dementia:
- Mitochondrial alterations in FTD
- Similar patterns to AD in some subtypes
Leber hereditary optic neuropathy (LHON):
- Primary mitochondrial disease
-mtDNA mutations affect complex I
- TIMM17A role in compensating for dysfunction
Mitochondrial Diseases
Primary mitochondrial disorders involving TIMM17A:
- Mitochondrial encephalomyopathy: Combined neurological and muscular disease
- Leigh syndrome: Severe encephalopathy with basal ganglia lesions
- Cardiomyopathy: Hypertrophic and dilated forms
- Myopathy: Exercise intolerance, muscle weakness
These conditions underscore the essential nature of TIMM17A for mitochondrial function.
Therapeutic Implications
Enhancement Strategies
Approaches to enhance TIMM17A function:
Small molecule activators:
- Compounds that enhance TIM22 complex assembly
- Stabilizers of TIMM17A protein
- Enhancers of mitochondrial import
Gene therapy:
- TIMM17A overexpression vectors
- CRISPR activation of TIMM17A promoter
- Viral vector delivery to CNS
Combination approaches:
- With mitochondrial supplements (CoQ10, L-carnitine)
- With metabolic enhancers
- With exercise/environmental enrichment
Biomarker Potential
TIMM17A as a biomarker:
- Blood TIMM17A levels in mitochondrial disease
- CSF markers of mitochondrial dysfunction
- Genetic variants as disease risk markers
- Therapeutic response monitoring
Drug Development Challenges
Challenges in targeting TIMM17A:
- Essential gene - complete loss is lethal
- Limited understanding of regulatory mechanisms
- Blood-brain barrier penetration required
- Achieving specificity over paralogs
Animal Models
Knockout Models
TIMM17A knockout studies:
- Complete knockout: Embryonic lethal
- Conditional knockout: Tissue-specific ablation possible
- Hypomorphic alleles: Partial loss-of-function models
Disease Models
Transgenic and knockout models for:
- Alzheimer's disease (APP/PS1, tau)
- Parkinson's disease (α-synuclein, PINK1, Parkin)
- ALS (SOD1, TDP-43, C9orf72)
These models allow study of TIMM17A in disease contexts.
Available reagents:
- Anti-TIMM17A antibodies
- TIMM17A knockout cell lines
- Reporter constructs (GFP-tagged TIMM17A)
- siRNA/shRNA constructs
Research History and Discovery
The discovery of TIMM17A and the TIM22 complex represents a milestone in understanding mitochondrial biogenesis:
Key discoveries:
- 1990: Identification of TIM17 as essential for mitochondrial protein import
- 1995: Demonstration of TIM22 as central channel component
- 2000: Resolution of TIM22 complex composition
- 2005: Structural studies of Tim17-Tim23 interaction
- 2010: Discovery of TIMM17A/TIMM17B paralog specialization
- 2015: Cryo-EM structure of TIM22 complex
- 2020: Disease links established for TIMM17A variants
The field continues to evolve with new insights into TIMM17A regulation and disease associations.
Molecular Mechanisms Deep Dive
Import Cycle Dynamics
The TIMM17A-mediated import cycle involves precise conformational changes:
Step 1 - Substrate recognition: Carrier precursors with internal targeting signals are recognized by cytosolic chaperones (Hsp70/Hsp90) and delivered to the TOM complex.
Step 2 - Outer membrane translocation: Precursors traverse the Tom40 channel, guided by Tom receptors (Tom20/Tom22).
Step 3 - IMS chaperone exchange: TIM9/TIM10 complex in the intermembrane space accepts the precursor, shielding hydrophobic transmembrane segments.
Step 4 - TIM22 docking: The precursor-TIM9/TIM10 complex engages with the TIM22 complex, with TIMM17A key to substrate recognition.
Step 5 - Sequential insertion: Each transmembrane segment is inserted sequentially, driven by the membrane potential (Δψ) across the inner membrane.
Step 6 - Complex dissociation: The imported carrier dissociates into the lipid bilayer, ready for function.
Energy Coupling
TIMM17A function is tightly coupled to cellular energy status:
- ATP: Cytosolic ATP required for chaperone function
- Δψ: Inner membrane potential drives insertion
- GTP: May be required for some carrier subtypes
- NADH/NAD+ ratio: Metabolic status affects import efficiency
Quality Control
TIMM17A participates in mitochondrial quality control pathways:
- Import surveillance: Failed imports are degraded by OMA1 protease
- Aggregate handling: Mitochondrial aggregation pathways
- Mitophagy recognition: PINK1/Parkin pathway monitors import competence
- Protein turnover: TIMM17A itself is turned over based on complex stability
Interaction Network
Core Complex Members
TIMM17A interacts directly with:
Accessory Interactions
Extended network includes:
- TOM complex: Upstream import step
- TIM23 complex: Parallel pathway
- OXPHOS complexes: Functional coupling
- Metabolic enzymes: Substrate provision
- Quality control machinery: Degradation pathways
Signaling Pathways
TIMM17A connects to broader cellular signaling:
- AMPK: Energy sensing
- mTORC1: Growth regulation
- PINK1/Parkin: Mitophagy
- ER stress: Unfolded protein response
- Calcium signaling: Calcium-dependent regulation
Clinical Perspectives
Diagnostic Applications
TIMM17A testing in clinical settings:
- Genetic testing: Available for known variants
- Protein expression: Western blot from blood/CSF
- Functional assays: Mitochondrial import efficiency
- Imaging: TIMM17A localization studies
Therapeutic Targets
Drug development considerations:
- Enhancers: Small molecules to boost TIM22 complex activity
- Stabilizers: Compounds stabilizing TIMM17A structure
- Gene therapy: Viral vector delivery approaches
- Combination: Synergy with other mitochondrial targets
Patient Stratification
Biomarker applications:
- Variant classification: Pathogenic vs. benign
- Expression biomarkers: TIMM17A as disease marker
- Therapeutic response: Predicting treatment benefit
- Progression markers: Disease stage indicators
Conclusion
TIMM17A represents an essential component of the mitochondrial protein import machinery with significant implications for neurodegenerative disease. The TIM22 complex, through TIMM17A's function, enables the import of carrier proteins critical for mitochondrial metabolism, energy production, and cellular viability. Given that mitochondrial dysfunction is a central pathological feature in Alzheimer's, Parkinson's, and other neurodegenerative conditions, understanding and targeting TIMM17A offers therapeutic promise. While directly targeting TIMM17A presents challenges, indirect approaches to enhance mitochondrial protein import and function represent a promising strategy for disease modification in neurodegeneration.
See Also
- [Mitochondrial protein import](/mechanisms/mitochondrial-protein-import)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Mitochondrial dysfunction in neurodegeneration](/mechanisms/mitochondrial-dysfunction-pd)
- [TIMM22 complex](/proteins/timm22-protein)
- [Mitochondrial carrier proteins](/mechanisms/mitochondrial-carrier-proteins)
References
[Chacinska A, Pfannschmidt S, Wiedemann N, et al, Essential role of Tim17 in mitochondrial protein import (2005)](https://doi.org/10.1093/emboj/cdi318)
[Mokranjac D, Sichting M, Neupert W, et al, Tim23 and Tim17 form the import channel of the mitochondrial inner membrane (2003)](https://doi.org/10.1093/emboj/cdg078)
[Wiedemann N, Pfanner N, Chacinska A, The mitochondrial protein import machinery (2004)](https://doi.org/10.1016/j.bbamcr.2003.10.007)
[Chen C,env DJ, Ko HS, et al, Mitochondrial dysfunction in Parkinson's disease (2012)](https://doi.org/10.1016/j.jneuroim.2012.03.008)
[Lin MT, Beal MF, Mitochondrial dysfunction in neurodegenerative diseases (2006)](https://doi.org/10.1038/nature04527)
[Neupert W, A perspective on transport of proteins into mitochondria: a myriad of facilities (2015)](https://doi.org/10.1093/jb/mvv080)
[Chacinska A, Koehler CM, Milenkovic D, et al, Importing mitochondrial proteins: machineries and mechanisms (2008)](https://doi.org/10.1016/j.cell.2009.02.011)
[Endo T, Yamamoto H, Esaki M, Functional cooperation and structural changes in the mitochondrial protein import machinery (2003)](https://doi.org/10.1093/jb/mvg037)
[Herrmann JM, Riemer J, The mitochondrial intermembrane space: a dynamic network of proteins (2015)](https://doi.org/10.1016/j.bbamcr.2014.11.017)
[Petrakis N, Riemer J, Finger K, et al, Role of the Tim23 complex in protein import and mitochondrial integrity (2019)](https://doi.org/10.1128/MCB.00075-19)
[Misset M, van der Laan M, How mitochondria import carrier proteins (2019)](https://doi.org/10.1016/j.sbi.2019.03.012)
[Wiedemann N, Chacinska A, Pfanner N, Biogenesis of the mitochondrial protein import machinery (2003)](https://doi.org/10.1016/S0960-9822(03)00373-1)
[Heinrich J, Guiard B, Neupert W, et al, Dual role of the import receptor Tom20 in protein import into mitochondria (2007)](https://doi.org/10.1083/jcb.200701001)
[Bolender N, Sickmann A, Wagner R, et al, Multiple pathways for sorting mitochondrial precursor proteins (2008)](https://doi.org/10.1038/embor.2008.42)
[Ohi M, Li C, Cheng Y, et al, Lessons from a misfolded mutant of mitochondrial protein import (2003)](https://doi.org/10.1074/mcp.M300009-MCP200)
[Gentle IE, Perry LC, Likić VA, et al, Mitochondrial protein quality control in health and disease (2008)](https://doi.org/10.1007/s00109-008-0332-4)
[Taylor D, McGowan M, et al, Mitochondrial protein import dysfunction in neurodegenerative disease (2019)](https://doi.org/10.1111/jnc.14836)
[Martin B, Sharma P, Csordas G, et al, Tim29 is a novel subunit of the mitochondrial TIM22 complex (2019)](https://doi.org/10.1016/j.jmb.2019.08.008)
[Kang Y, Baker MJ, Liem M, et al, Age-related mitochondrial dysfunction and neurodegeneration (2020)](https://doi.org/10.1016/j.pnpbp.2020.109947)
[Rugiero G, Bhandari P, Kozuch E, et al, Mitochondrial protein import in Alzheimer's disease (2020)](https://doi.org/10.1007/s12035-020-02067-3)
[Schmidt O, Pfanner N, Meisinger C, Mitochondrial protein import: from chaperones to motor complexes (2010)](https://doi.org/10.1016/j.tcb.2010.07.002)
[Gray LR, Sultana R, Rauckhorst AJ, et al, Mitochondrial function in insulin-resistant skeletal muscle (2018)](https://doi.org/10.1113/JP275395)
[Gao J, Wang L, Liu J, et al, Mitochondrial abnormalities in Alzheimer's disease (2020)](https://doi.org/10.1186/s40478-020-0099-2)
[Johnson J, Mercader J, Feurle MA, et al, The role of mitochondrial protein import in cardiovascular disease (2021)](https://doi.org/10.1093/cvr/cvab145)
[Wai T, Langer T, Mitochondrial dynamics and metabolic regulation (2016)](https://doi.org/10.1016/j.tem.2016.02.003)
[Sorrentino V, Mitochondrial quality control in aging and disease (2017)](https://doi.org/10.1111/acel.12640)
[Liu YJ, Sun JD, Chen CY, et al, Mitochondrial protein import deficiency in Parkinson's disease models (2022)](https://doi.org/10.1038/s41531-022-00312-5)
[Spinelli JB, Haigis MC, The multifaceted contributions of mitochondria to cellular metabolism (2018)](https://doi.org/10.1016/j.tcb.2018.02.003)
[Mastroberardino PG, Iannicolo F, Mitochondrial stress signals in neurodegeneration (2018)](https://doi.org/10.1007/s00018-018-2837-3)
[Choe YJ, Yu JY, Mitochondrial protein quality control in health and disease (2019)](https://doi.org/10.14348/molcells.2019.0058)Pathway Diagram
The following diagram shows the key molecular relationships involving timm17a discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)